These data support a role for PRL-3 in BCR-ABL signalling and CML biology and may be a potential therapeutic target downstream of BCR-ABL in TKI resistant mutant cells. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.